Artificial intelligence documentation firm Abridge announced partnerships with pharmaceutical company Eli Lilly and technology company Nvidia on Thursday to broaden its platform beyond clinical note-taking. The move aims to integrate AI more deeply with payers and life science companies to accelerate claims resolution and clinical trial screening.
Abridge is working with Nvidia to develop a foundation model specifically designed for clinical conversations. Simultaneously, Eli Lilly is making an undisclosed strategic investment in the company. "The investment is to support evidence-based care and research access at all the moments of care," Abridge CEO Shiv Rao said during a keynote presentation.
Market position and platform growth
Founded in 2018, Abridge raised two nine-digit funding rounds last year and now serves over 300 health systems, including Kaiser Permanente and Johns Hopkins Medicine. Chicago-based Northwestern Medicine also plans to deploy the tools across its system. The AI scribe market remains highly competitive, with electronic health record vendors like Epic and Oracle Health entering the space and embedding their own tools directly into existing clinician workflows.
To differentiate its offering, Abridge is adding capabilities for pre-visit patient summaries and clinical query tools. The company has also partnered with the American Diabetes Association, the American Academy of Family Physicians, and medical journals including Neurology and the Journal of Clinical Oncology to enrich its clinical decision support. This broader push into automated patient records requires healthcare systems to rethink documentation workflows, a shift increasingly supported by targeted AI Learning Path for Medical Records Clerks.
Payer and clinical trial integration
The platform will now use medical record data to identify and screen potential candidates for clinical trials. On the financial side, Abridge is collaborating with the American Health Information Management Association to ensure its coding capabilities meet standards for fee-for-service and value-based care reimbursement.
This push to connect with insurers arrives as health plans worry that provider use of AI documentation and billing tools could drive up healthcare costs. If payers adopt their own automated claims review products, provider and insurer AI systems may end up conflicting over reimbursement decisions.
Why this matters for healthcare professionals
Healthcare workers should expect AI tools to move beyond simple transcription and directly influence billing and research workflows. Clinicians and administrators must verify how these systems code encounters and screen patients, as automated decisions will increasingly dictate both revenue cycles and trial eligibility.
Your membership also unlocks:
